## Does toll-like receptor 3 play a biological role in virus infections?

Kurt H. Edelmann<sup>1</sup>, Sarah Richardson-Burns<sup>2</sup>, Lena Alexopoulou<sup>3</sup>, Kenneth L. Tyler<sup>4</sup>, Richard A. Flavell<sup>3</sup>, and Michael B.A. Oldstone<sup>1</sup>

- The Scripps Research Institute, Division of Virology, Department of Neuropharmacology, La Jolla, CA 92037, USA.
- Program in Neuroscience, University of Colorado Health Sciences Center, Denver, CO 80262
- Section of Immunobiology and the Howard Hughes Medical Institute, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT
- Departments of Neurology, Medicine, Microbiology & Immunology University of Colorado Health Sciences Center, Denver, Colorado 80262, USA

#### Abstract

The Toll-like receptor family functions to recognize conserved microbial and viral structures with the purpose of activating signal pathways to instigate immune responses against infections by these organisms. For example *in vitro* studies reveal that TLR3 ligand is double stranded RNA, a product of viral infections. On the basis of this observation it has been proposed that TLR3 is likely an important first signal for virus infections. We approached this issue by investigating the role of TLR3 in four different infectious viral models (LCMV, VSV, MCMV and reovirus), and in TLR3 genetically deficient (<sup>-/-</sup>) mice. Our results indicate that TLR3 is not universally required for the generation of effective antiviral responses since the absence of TLR3 does not alter either viral pathogenesis or impair host's generation of adaptive antiviral responses to these viruses.

#### Introduction

Ten distinct mammalian toll-like receptors (TLRs) have been described, most of which have been shown to function as receptors for pathogen associated molecular patterns (Akira and Hemmi, 2003; Takeda, Kaisho, and Akira, 2003). These receptors aid the host to combat infection as microbial ligands upon binding to various TLRs on antigen presenting cells (APCs) trigger NF- $\kappa$ B leading to the upregulation of cytokines and costimulatory molecules with the presumed purpose of initially enhancing innate immune attack against the pathogen from which that ligand is derived (Aderem and Ulevitch, 2000; Anderson, 2000; Hallman, Ramet, and Ezekowitz, 2001; Kopp and Medzhitov, 1999). It has been hypothesized that loss of function of particular TLRs causes the host to become more susceptible to infections with TLR-reactive pathogens. Evidence supporting this concept come from observations where the loss of TLR2 has resulted in increased susceptibility to Staphylococcus aureus infections (Takeuchi, Hoshino, and Akira, 2000), loss of TLR9 resulted in ablation of the immunostimulatory properties of bacterial DNA (Hemmi et al., 2000), and loss of TL4 resulted in increased susceptibility to respiratory syncytial virus (Kurt-Jones et al., 2000). These results led to the proposal that TLR3, a receptor demonstrated to be reactive to double stranded (ds) RNA (Alexopoulou et al., 2001; Matsumoto et al., 2002), a frequent byproduct of virus replication, functions as a universal virus receptor for priming the innate immune system to viral infections.

Of the TLRs studied only TLR3 has been identified to respond to dsRNA (Alexopoulou et al., 2001) by specifically recognizing poly (I:C) and purified Lang reovirus genomic dsRNA both of which resulted in the induction of IFN- $\beta$ , IL-12, IL-6 and TNF $\alpha$  from macrophages obtained from TLR3 sufficient mice. The ability of TLR3 to induce IFN- $\beta$  has been attributed to at least two factors: its MyD88-independent activation of IRF3 and to its induction of the traditional ds-RNA-dependent protein kinase (PKR) pathway (Doyle et al., 2002; Horng, Barton, and Medzhitov, 2001; Oshiumi et al., 2003). Recognition of dsRNA ligand has been demonstrated to occur extracellularly through the use of TLR3-blocking antibodies which prevented TLR3-

p3

mediated responses to poly (I:C) in vitro (Matsumoto et al., 2002). In vivo studies using TLR3 deficient (<sup>-/-</sup>) mice showed protection of such mice from shock induced by poly (I:C) treatment suggesting this receptor contributed to the in vivo recognition of and responses to extracellular dsRNA (Alexopoulou et al., 2001). Furthermore, it was shown that the effector responses elicited by TLR3:poly (I:C) interaction can inhibit murine T herpesvirus 68 replication in bone marrow-derived macrophage cultures (Doyle et al., 2002). Based on the above findings it has been repeatedly assumed that TLR3 likely played an important role in host defense against virus infections (Akira and Hemmi, 2003; Alexopoulou et al., 2001; Doyle et al., 2002; Harte et al., 2003; Matsumoto et al., 2002; Renshaw et al., 2002). However it has not yet been determined if the physiologic amounts of dsRNA naturally made during viral infections per se were sufficient to trigger through TLR3 a biologically meaningful response to alter the outcome of disease. We set out to experimentally determine if TLR3 is essential for antiviral immunity or if TLR3 represents an expendable level of redundancy built into the dsRNA recognition system. Here we report our work that directly tests this hypothesis by studying both host immune responses and control of infection by a dsRNA virus, reovirus; two ssRNA viruses that make dsRNA intermediates, lymphocytic choriomeningitis virus (LCMV) and vesicular stomatitis virus (VSV); and a DNA virus, murine cytomegalovirus (MCMV) in TLR3 gene disrupted mice. Our results indicate that TLR3 does not play a critical role in the host anti-viral adaptive immune response to reovirus, LCMV, VSV, or MCMV as susceptibility to infection and generation of CD4 and CD8 T cell immune responses to these viruses are equivalent in TLR3 deficient and sufficient mice.

#### **Results and Discussion**

Our initial experiments studied the primary adaptive immune responses to LCMV infection in TLR3<sup>-/-</sup> mice. LCMV is an arenavirus containing a genome consisting of two negative stranded RNAs, and like the other viruses investigated in this report is able to trigger Type-I IFNs. Control of acute LCMV infection is totally mediated by virusspecific CD8<sup>+</sup> T cells through a perforin mediated pathway (Anderson et al., 1985; Kagi et al., 1995). To test if TLR3 plays a role in the immune response to LCMV, TLR3<sup>-/-</sup> mice and control C57Bl/6 (B6)x129 mixed background mice bred at TSRI vivarium were inoculated intraperitoneally with  $1 \times 10^5$  pfu LCMV ARM53b. IFNy responses from LCMV specific T cells were assessed 8 days post infection via intracellular cytokine staining and flowcytometry following a 5 hour culture of splenocytes with brefeldin A, rIL2, and CD8 and CD4 LCMV-specific H-2<sup>b</sup>-specific peptide epitopes, GP61 (aaGP61-80) and GP33 (aa GP33-41) respectively (Hudrisier, Oldstone, and Gairin, 1997; Murali-Krishna et al., 1998; Whitmire et al., 1998). TLR3<sup>-/-</sup> mice showed no difference compared to controls in their ability to generate both a robust  $CD8^+$  and  $CD4^+$  IFN $\gamma$ response to LCMV (Fig. 1A). Furthermore LCMV-specific CD8<sup>+</sup> T cells from TLR3<sup>-/-</sup> mice also displayed normal lysis of GP33 peptide-coated H-2<sup>b</sup>-MC57 targets cells (Fig.1B).

Hosts usually encounter pathogens during natural infections at significantly lower concentrations than utilized in many laboratory infectious models. To investigate a role for TLR3 during a low level infection, we conducted experiments in which both the dose and route of inoculation of LCMV was varied. A series of ip and foot pad inoculations with doses of LCMV ranging from as little as  $1 \times 10^2$  pfu to  $5 \times 10^5$  pfu LCMV were carried out and CD8<sup>+</sup> T cell IFN $\gamma$  responses from both the draining lymph nodes and spleen were analyzed (Fig.1C). Intravenous injection of a very high dose of LCMV ( $2 \times 10^6$ pfu) was also analyzed (data not shown), however irrespective of the route and dose of virus inoculation the absence of TLR3 did not affect the generation of the primary cellular response to LCMV.

We next assayed the primary T cell responses to a RNA virus, VSV, and a DNA virus, MCMV, in TLR3<sup>-/-</sup> mice. VSV, a member of the Rhabdovirus family, contains a single stranded negative sense RNA genome and control of VSV in mice is dependent on

p4

the generation of virus-specific antibodies and complement (Lefrancois, 1984; Steinhoff et al., 1995). Furthermore, VSV infection leads to induction of Type-I IFNs triggered, in part, by the prevalence of structured dsRNA defective interfering particles found during VSV infection(Holland, 1987). We found that TLR3<sup>-/-</sup> mice handle VSV infection as well as B6x129 control mice. Mice infected with VSV generated both CD4<sup>+</sup> and CD8<sup>+</sup> VSV-specific T cell responses to peptides NP415 and NP52 respectively (Fig.2A) and were able to clear the virus (data not shown). MCMV is a dsDNA herpes virus that, like LCMV, is a natural pathogen of mice. MCMV infection of susceptible strains of mice results in lifelong latent infection punctuated by spontaneous reactivation from the latent state. Protection of the host from lethal MCMV infection is complex requiring contributions from both the innate and adaptive immune response(Koszinowski, Del Val, and Reddehase, 1990). The effect of the loss of TLR3 on the T cell response to MCMV in TLR3<sup>-/-</sup> mice was analyzed day 9 post infection with  $1 \times 10^4$  pfu ip. T cell IFNy responses were measured after 5 hour culture in aCD3 coated wells since there are no currently defined H-2<sup>b</sup> T cell peptide epitopes for MCMV. These analyses did not identify differences between control and TLR3<sup>-/-</sup> mice in the primary T cell response to MCMV (Fig.2B). Furthermore the spleens from these mice were free of virus indicating that the absence of TLR3 did not increase the susceptibility to MCMV (data not shown).

Next we determined the role TLR3 played in functional T cell memory responses. Intravenous inoculation of naïve or immunosuppressed mice with LCMV variant Cl 13  $(2x10^{6} \text{ pfu})$  leads to establishment of persistent infection (Ahmed et al., 1984). In contrast mice previously immunized with LCMV ARM53b develop T cell memory responses that are able to prevent establishment of persistent infection by subsequent LCVM Cl 13 challenge (Arbour et al., 2002). TLR3<sup>-/-</sup> mice were tested for the ability to generate a lasting functional memory response to LCMV infection. LCMV immune TLR3<sup>-/-</sup> and control mice  $(1x10^{5} \text{pfu} \text{ LCMV ARM53b ip})$  were inoculated 3 months after primary challenge with  $2x10^{6}$  pfu LCMV Cl 13 via iv injection. The CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses of these mice were analyzed 3 days after inoculation. All mice showed levels of IFN- $\gamma^{+}$  LCMV-specific T cells that were not statistically different indicating normal induction of the T cell memory response (Fig.2C).

The last series of studies employed a double stranded RNA virus infection of neonatal TLR3<sup>-/-</sup> and control mice using Type 3 reovirus strain Dearing (T3D). Intracerebral inoculation of neonatal mice is the classic experimental model for evaluating virulence of neurotropic viruses such as reovirus. We therefore compared mortality, viral titer, antigen distribution, and neuropathology in newborn TLR3<sup>-/-</sup> and control TLR3<sup>+/+</sup> injected intracerebrally with T3D. There was no difference between T3D-infected TLR3<sup>+/+</sup> control mice and T3D-infected TLR3<sup>-/-</sup> mice in virus-induced CNS injury. The localization and the severity of viral CNS pathology was similar in both strains of mice, with the brunt of virus-induced injury present in the CA2-3 region of the hippocampus, cingulate gyrus, fronto-parietal cortex, and dorsal thalamus as previously reported (Fig. 3b-c) (Oberhaus et al., 1997; Raine and Fields, 1973; Richardson-Burns, Kominsky, and Tyler, 2002). CNS injury is evidenced by the presence of numerous pyknotic and apoptotic cells, some infiltrating inflammatory cells, disruption of cytoarchitecture, and loss of tissue integrity (see Fig. 3). Viral antigen co-localized with areas of CNS injury with anti-T3D immunohistochemical staining present in the hippocampus, cortex, and thalamus. Figure 4 shows viral antigen staining in the dorsal thalamus and CA3 region of the hippocampus from T3D-infected TLR3<sup>+/+</sup> and TLR3<sup>-/-</sup> mice (Fig. 4). There was no difference in survival between T3D-infected TLR3<sup>+/+</sup> and control mice. Mortality was 40% by day 7 in TLR3<sup>-/-</sup> mice, with all 6 survivors appearing moribund. Mortality was 37.5% in control TLR3<sup>+/+</sup> mice with all five survivors appearing moribund. Mean weight of mice on day of sacrifice (d7) was 3.53 gms for TLR3<sup>-/-</sup> mice and 3.90 gms for TLR3<sup>+/+</sup> control mice. Viral titer in brain at time of sacrifice was the same in the two groups of mice  $(8.94 + 0.06 \log_{10} \text{ pfu/ml in TLR3}^{-/-})$ mice compared to 9.00 + 0.13 in control TLR<sup>+/+</sup> mice).

In summary, our data indicate that the TLR3 signaling pathway does not appear to influence the generation of effective anti-viral responses for a range of virus infections thereby calling into question whether it represents a universal element in antiviral immunity. Although we did not observe enhanced susceptibility with our strain and dose of MCMV, others (Hoebe et al 2003) using mice deficient in lps2, a downstream component of the TLR3 signaling pathway, noted increased susceptibility to MCMV at higher doses of virus. So it appears that there may be some conditions where TLR3 does

enhance immunity, and that it may be restricted to the early control of an overwhelming viral infection requiring a fast and strong IFN type-I innate response to prevent host death. One question that arises from the current studies is whether TLR3 can in fact recognize any component of these viruses. Using an in vitro assay where the various TLR genes are transfected and expressed in HeLa and HEK cells, UV inactivated-LCMV Arm 53b and other arenaviruses were unable to activate cells expressing TLR3 while control poly I:C did, again indicating that TLR3 is unlikely to play a role in the pathogenesis of arenaviruses. However, several of these arenaviruses did activate other TLR receptors (de Silva and Kunz, unpublished observations, manuscript in preparation). It is also possible that TLR3 is not capable of recognizing the viral RNA intermediates of LCMV, VSV and MCMV. This is not true for reovirus where Alexopoulou et al (Alexopoulou et al., 2001) identified TLR3 recognition of purified reovirus genomic dsRNA. Hence it is possible that during the course of these viral infections that TLR3 never comes in contact with unsequestered or exposed viral RNAs. Alternatively and a more likely scenario is that the concentrations of dsRNA made during natural infection is not sufficient to bind to and significantly influence TLR3 signaling when compared to the high concentrations used for in vitro studies.

#### **Materials & Methods**

#### Mice

TLR3<sup>-/-</sup> mice on C57BL/6x B129 mixed background and matched control mice were derived at Yale University and bred at The Scripps Research Institute. Mice were bred and maintained under specific pathogen-free conditions.

#### Virus Strains

Stocks of both LCMV ARM 53b and variant LCMV Cl 13 were grown up via single passage in baby hamster kidney (BHK) cells from stocks that had been previously triple plaque purified in Vero cells (Ahmed et al., 1984; Dutko and Oldstone, 1983). VSV stocks were generated by collection of supernatants from 100% CPE VSV-infected BHK-21 cells (Lyles, McKenzie, and Parce, 1992). Stocks of the Smith strain of MCMV of virus derived from *in vivo* propagation in salivary glands of Balb/c mice were obtained from Dr. Raymond Welsh at the University of Massachusetts Medical School, Worcester MA (Bukowski, Woda, and Welsh, 1984). Reovirus strain type 3 Dearing (T3D) was identified, passaged, and quantitated as previously reported (Tyler et al., 1985; Tyler et al., 1989).

#### LCMV, VSV, MCMV methods

LCMV ARM 53b was inoculated into mice intraperitoneally with either  $5 \times 10^3$  pfu,  $1 \times 10^5$  pfu, or  $5 \times 10^5$  pfu where noted. Footpad injection experiments with LCMV ARM 53b were conducted with  $1 \times 10^2$  pfu or  $5 \times 10^2$  pfu virus. Secondary challenges with LCMV Cl 13 were performed intravenously with a dose of virus previously demonstrated to result in persistent infection in naïve mice ( $2 \times 10^6$  pfu). In experiments using VSV, virus was injected intravenously at a dose of  $2 \times 10^6$  pfu. Mice infected with MCMV were inoculated intraperitoneally with  $1 \times 10^4$  pfu virus.

#### Reovirus methods

2 day-old neonatal mice (weight 1.5-2g), were used in reovirus T3D studies. 8 control (C57BL/6 x 129) and 10 TLR3<sup>-/-</sup> mice on the same background were infected with  $10^7$  pfu of T3D intracerebrally in a 10 µl volume using a 29g needle connected to a Hamilton

p8

microsyringe. Animals were sacrificed for tissue collection at day 7 post-infection, by which time all animals were moribund. Tissue was collected for histology, immunocytochemistry and determination of viral titer by plaque assay. T3D-infected and 5 were not virally infected (uninfected control). 9 TLR3<sup>-/-</sup> mice were T3D-infected. Mice were inoculated with T3D (1X10<sup>5</sup> PFU) via intracerebral/intracranial (*ic*) injection with each mouse pup weighing about 1.7g. Injections were made using a 29 gauge needle in a 10µl volume. Animals were sacrificed by decapitation 7 days after infection.

#### Analysis of T cell responses

All data represents averages of results from individual mice with 3-5 per group. Splenocytes from LCMV or VSV infected mice were cultured for 5 hours in RPMI 7%FCS with 50U/ml rIL2 and 1 $\mu$ g/ml MHC class-I or class-II restricted peptides. T cells from MCMV mice were cultured for 5 hours in  $\alpha$ -CD3 coated wells in RPMI-7%FCS + 50U/ml rIL2. 1 $\mu$ g/ml brefeldin A was added to all cultures at least 3hours prior to staining. Surface and intracellular staining procedures were performed as previously described using CD4-FITC, CD8-PE and IFN $\gamma$ -APC antibodies(Homann et al., 1998). Antibodies used in these experiments were obtained from Pharmingen. CD8<sup>+</sup> T cell cytolytic function was measured by standard 5 hour<sup>51</sup>Cr release assay using MC57 and BALB17 mouse fibroblasts coated with LCMV peptide GP33-41 (1hr incubation with 1 $\mu$ g/ml peptide followed by 3 washes).

### $MHC H-2^b$ restricted peptides

Peptides were obtained from PeptidoGenic Research . Peptide used were: LCMV MHC Class-I: GP33-41, NP396-404; LCMV MHC Class-II: GP61-80 VSV MHC Class-I: NP52-59; VSV MHC Class-II GP 415-433

#### Histology

For histopathologic and immunohistochemical staining, 5 or 6 whole mouse brains per treatment group were fixed by immersion in 10% buffered formalin for 24-30h at room temperature (RT), then cut in half along the mid-coronal line for sectioning. Fixed tissues were transferred to 70% ethanol, paraffin-embedded, and sectioned at 4 µm thickness.

p9

For each animal, 2 coronal sections were stained with hematoxylin and eosin (H&E) for studies of the extent of virus-induced pathology. Paraffin-embedded sections were baked at 57°C for 5 min to enhance antigen retrieval, then de-paraffinized by immersion in mixed xylenes followed by rehydration in a series of descending ethanol concentrations followed by PBS.

#### Immunohistochemistry

Brain tissue sections were de-paraffinized by baking for 5 min at 57°C, immersion in mixed xylenes, then rehydration in graded alcohols. For viral antigen staining, deparaffinized tissues were permeabilized in PBS/0.1% triton X (PBSX) for 1h at room temperature (RT) , then non-specific binding was blocked in 3% BSA/PBS for 1h at RT. Tissue was incubated with primary antibody anti-T3D polyclonal (laboratory stock) diluted (1:200) in 3% BSA/PBSX for 1h at 37 °C, then washed in PBSX. Secondary antibody anti-rabbit-Alexafluor594 (Molecular Probes, Eugene OR) diluted 1:100 in 1.5% BSA/PBSX was incubated with tissue for 1h at RT in the dark. Tissues were washed in PBSX, exposed to Hoechst 33342 (Molecular Probes) diluted in PBS for 5 min at RT, washed in PBSX, then aqueous mounted with Vectashield (Vector Laboratories Inc, Burlingame, CA). All images were captured by digital bright-field or fluorescence microscopy at 25-100X magnification using a Zeiss Axioplan 2 Digital Microscope with Cooke SensiCam 32 bit Camera.

#### Determination of viral titer

Reovirus T3 titer in brain tissue was determined by standard plaque assay techniques on confluent monolayers of L929 fibroblasts. Specimens were frozen (-70 C.) and thawed (RT) three times, briefly sonicated and then diluted into gelatinized saline. Duplicate aliquots were serially diluted in 10-fold steps and samples from at least three consecutive dilutions were inoculated onto L929 cell monolayers. Monolayers were stained with neutral red dye at day 6 post infection and plaques counted. Viral titer was determined by averaging the number of plaques seen at the most informative dilution and correcting for inoculum size and dilution factor. Results are presented as  $Log_{10}$  plaque forming units (pfu)/ml + SEM.

Fig. 1 Absence of TLR3 does not affect primary CD4<sup>+</sup> or CD8<sup>+</sup> T cell responses to LCMV. TLR3-/- mice and control mice (n=3 mice per group) were infected with LCMV ARM53b ( $1x10^{5}$  pfu ip) infection with TLR3<sup>-/-</sup> and control splenocytes were obtained 8 days later. (A) Cells were stimulated *in vitro* with either LCMV-specific CD4<sup>+</sup> or CD8<sup>+</sup> T cell peptide epitopes in the presence of brefeldin A. IFNy responses were measured by intracellular cytokine staining in combination with CD8<sup>+</sup> and CD4<sup>+</sup> surface staining. Results are represented as percentage of IFN $\gamma$  positive cells within respective CD4<sup>+</sup> or CD8<sup>+</sup> populations. (B) Measurement of CD8<sup>+</sup> T cell lytic function was assessed via standard chromium release assay against GP33 peptide coated syngeneic and allogeneic cells; MC57 and BALB17 cells respectively. (C) TLR3<sup>-/-</sup> mice respond efficiently to LCMV irrespective of route and dose of inoculation. TLR3<sup>-/-</sup> and control mice (n=3-4mice per group per condition) were inoculated with LCMV ARM 53b using either foot pad or ip injection and varying doses as indicted. IFNy responses from GP-33 specific T cells were analyzed 8 days post infection from draining lymph nodes in foot pad injected mice and splenocytes from ip injected mice. Results are represented as percent IFN $\gamma^+$  $CD8^+$  T cells of total  $CD8^+$  T cell population. Data represented in (A) and (B) are derived from individual experiments while those for (C) are compiled from several experiments.

Fig. 2. (A-B) Primary T cell response to VSV and MCMV are normal in TLR3<sup>-/-</sup> mice. Splenocytes were isolated from TLR3-/- and control mice 8 days post infection with VSV  $(2x10^{6} \text{ pfu iv})$  or 9 days post infection with MCMV  $(1x10^{4} \text{ pfu ip})$ . Cells from VSV infected mice were stimulated for 5 hours with either CD8-specific peptide epitope NP52 or CD4-specific peptide epitope NP415 while cells from MCMV infected mice were stimulated with  $\alpha$ -CD3. Groups consisted of 3-4 mice. All data represent averages of results from individual mice derived from three experiments and are represented as percent IFN $\gamma^+$  T cells of respective CD8<sup>+</sup> or CD4<sup>+</sup> T cell populations.

(C) TLR3<sup>-/-</sup> mice have functional T cell memory responses. TLR3<sup>-/-</sup> and control mice (n=2 per group) were immunized with LCMV Arm 53b ( $1x10^5$  pfu ip). These mice were challenged with LCMV Cl 13 ( $2x10^6$  pfu iv) three months after immunization. Splenocytes were isolated three days post secondary challenge and responses to CD4 peptide epitope GP61, and CD8 peptide epitopes GP33 and NP396 were measured. Results are presented as % IFN $\gamma^+$  cells of either CD4<sup>+</sup> or CD8<sup>+</sup> cell populations.

Fig. 3 There is no difference between TLR3-deficient mice and wild-type mice in T3 reovirus-induced injury or T3 reovirus antigen expression in the CNS. (A) Uninfected control mouse brain stained with hematoxylin and eosin (H&E) shows normal CNS cytoarchitecture and normal appearing nuclei of viable cells. (B) H&E stained brain from T3D-infected TLR3<sup>+/+</sup> wild-type mouse shows characteristic T3 reovirus-associated injury throughout the brain evidenced by cell death, loss of normal cytoarchitecture, and loss of tissue integrity in the cingulate gyrus (CG), fronto-parietal cortex (FPC), hippocampus (HC), and thalamus (THA). (C) H&E stained brain from T3D-infected TLR3<sup>-/-</sup>) mouse show T3 reovirus-induced CNS injury comparable to that seen in T3D-infected TLR<sup>+/+</sup> wild-type mice. (\* = brain region with viral injury, cell loss, apoptotic cells, and loss of cytoarchitecture), (arrow = brain region with cell loss).

Fig. 4 There is no difference between TLR3-deficient mice and wild-type control mice in T3 reovirus-induced injury in the CNS. (A) Immunohistochemistry (IHC) for T3 reovirus antigen shows numerous T3D positive cells (dark brown) in brains of T3D-infected TLR3<sup>+/+</sup> wild-type control mice. Antigen staining is evident in the same brain regions in which T3 reovirus injury is present (compare to Fig. 3). (B) IHC for T3 reovirus antigen in brain of T3D-infected TLR3<sup>-/-</sup> mouse shows similar antigen levels to that seen in the T3D-infected TLR3<sup>+/+</sup> wild-type control mouse brains.

#### Acknowledgments

This work is supported by US Public Health grants from the NIH AI09484 and AI45927 (KHE, MBAO), VA MERIT and REAP Awards (KLT) and Department of Defense Grant DAMD 17-98-1-8614 (SR-B, KLT), Howard Hughes Investigator award (RAF), and NIH training grant NS41219 (KHE). The authors thank Bruce Beutler and Philippe Georgel at TSRI for helpful comments.

#### References

- Aderem, A., and Ulevitch, R. J., 2000. Toll-like receptors in the induction of the innate immune response. Nature 406, 782-7.
- Ahmed, R., Salmi, A., Butler, L. D., Chiller, J. M., and Oldstone, M. B., 1984. Selection of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently infected mice. Role in suppression of cytotoxic T lymphocyte response and viral persistence. J Exp Med 160, 521-40.
- Akira, S., and Hemmi, H., 2003. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett 85, 85-95.
- Alexopoulou, L., Holt, A. C., Medzhitov, R., and Flavell, R. A., 2001. Recognition of double-stranded RNA and activation of NF-kappaB by Toll- like receptor 3. Nature 413, 732-8.
- Anderson, J., Byrne, J. A., Schreiber, R., Patterson, S., and Oldstone, M. B., 1985. Biology of cloned cytotoxic T lymphocytes specific for lymphocytic choriomeningitis virus: clearance of virus and in vitro properties. J Virol 53, 552-60.
- Anderson, K. V., 2000. Toll signaling pathways in the innate immune response. Curr Opin Immunol 12, 13-9.
- Arbour, N., Naniche, D., Homann, D., Davis, R. J., Flavell, R. A., and Oldstone, M. B., 2002. c-Jun NH(2)-terminal kinase (JNK)1 and JNK2 signaling pathways have divergent roles in CD8(+) T cell-mediated antiviral immunity. J Exp Med 195, 801-10.
- Bukowski, J. F., Woda, B. A., and Welsh, R. M., 1984. Pathogenesis of murine cytomegalovirus infection in natural killer cell- depleted mice. J Virol 52, 119-28.
- Doyle, S., Vaidya, S., O'connell, R., Dadgostar, H., Dempsey, P., Wu, T., Rao, G., Sun, R., Haberland, M., Modlin, R., and Cheng, G., 2002. IRF3 mediates a TLR3/TLR4-specific antiviral gene program. Immunity 17, 251-63.
- Dutko, F. J., and Oldstone, M. B., 1983. Genomic and biological variation among commonly used lymphocytic choriomeningitis virus strains. J Gen Virol 64, 1689-98.
- Hallman, M., Ramet, M., and Ezekowitz, R. A., 2001. Toll-like receptors as sensors of pathogens. Pediatr Res 50, 315-21.
- Harte, M. T., Haga, I. R., Maloney, G., Gray, P., Reading, P. C., Bartlett, N. W., Smith, G. L., Bowie, A., and O'neill, L. A., 2003. The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense. J Exp Med 197, 343-51.
- Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., and Akira, S., 2000. A Toll-like receptor recognizes bacterial DNA. Nature 408, 740-5.
- Hoebe, K., Du, X., Georgel, P., Janssen, E., Tabeta, K., Kim, S. O., Goode, J., Lin, P., Mann, N., Mudd, S., Crozat, K., Sovath, S., Han, J., and Beutler, B., 2003.
  Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. Nature 424, 743-8.
- Holland, J. (1987). Defective-interfering rhabdoviruses. *In* "The Rhabdoviruses" (R. Wagner, Ed.), pp. 297-360. Plenum, New York.

- Homann, D., Tishon, A., Berger, D. P., Weigle, W. O., Von Herrath, M. G., and Oldstone, M. B., 1998. Evidence for an underlying CD4 helper and CD8 T-cell defect in B-cell- deficient mice: failure to clear persistent virus infection after adoptive immunotherapy with virus-specific memory cells from muMT/muMT mice. J Virol 72, 9208-16.
- Horng, T., Barton, G. M., and Medzhitov, R., 2001. TIRAP: an adapter molecule in the Toll signaling pathway. Nat Immunol 2, 835-41.
- Hudrisier, D., Oldstone, M. B., and Gairin, J. E., 1997. The signal sequence of lymphocytic choriomeningitis virus contains an immunodominant cytotoxic T cell epitope that is restricted by both H- 2D(b) and H-2K(b) molecules. Virology 234, 62-73.
- Kagi, D., Seiler, P., Pavlovic, J., Ledermann, B., Burki, K., Zinkernagel, R. M., and Hengartner, H., 1995. The roles of perforin- and Fas-dependent cytotoxicity in protection against cytopathic and noncytopathic viruses. Eur J Immunol 25, 3256-62.
- Kopp, E. B., and Medzhitov, R., 1999. The Toll-receptor family and control of innate immunity. Curr Opin Immunol 11, 13-8.
- Koszinowski, U. H., Del Val, M., and Reddehase, M. J., 1990. Cellular and molecular basis of the protective immune response to cytomegalovirus infection. Curr Top Microbiol Immunol 154, 189-220.
- Kurt-Jones, E. A., Popova, L., Kwinn, L., Haynes, L. M., Jones, L. P., Tripp, R. A.,
  Walsh, E. E., Freeman, M. W., Golenbock, D. T., Anderson, L. J., and Finberg, R.
  W., 2000. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 1, 398-401.
- Lefrancois, L., 1984. Protection against lethal viral infection by neutralizing and nonneutralizing monoclonal antibodies: distinct mechanisms of action in vivo. J Virol 51, 208-14.
- Lyles, D. S., Mckenzie, M., and Parce, J. W., 1992. Subunit interactions of vesicular stomatitis virus envelope glycoprotein stabilized by binding to viral matrix protein. J Virol 66, 349-58.
- Matsumoto, M., Kikkawa, S., Kohase, M., Miyake, K., and Seya, T., 2002. Establishment of a monoclonal antibody against human Toll-like receptor 3 that blocks doublestranded RNA-mediated signaling. Biochem Biophys Res Commun 293, 1364-9.
- Murali-Krishna, K., Altman, J. D., Suresh, M., Sourdive, D. J., Zajac, A. J., Miller, J. D., Slansky, J., and Ahmed, R., 1998. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity 8, 177-87.
- Oberhaus, S. M., Smith, R. L., Clayton, G. H., Dermody, T. S., and Tyler, K. L., 1997. Reovirus infection and tissue injury in the mouse central nervous system are associated with apoptosis. J Virol 71, 2100-6.
- Oshiumi, H., Matsumoto, M., Funami, K., Akazawa, T., and Seya, T., 2003. TICAM-1, an adaptor molecule that participates in Toll-like receptor 3- mediated interferonbeta induction. Nat Immunol 4, 161-7.
- Raine, C. S., and Fields, B. N., 1973. Reovirus type 3 encephalitis--a virologic and ultrastructural study. J Neuropathol Exp Neurol 32, 19-33.

- Renshaw, M., Rockwell, J., Engleman, C., Gewirtz, A., Katz, J., and Sambhara, S., 2002. Cutting edge: impaired Toll-like receptor expression and function in aging. J Immunol 169, 4697-701.
- Richardson-Burns, S. M., Kominsky, D. J., and Tyler, K. L., 2002. Reovirus-induced neuronal apoptosis is mediated by caspase 3 and is associated with the activation of death receptors. J Neurovirol 8, 365-80.
- Steinhoff, U., Muller, U., Schertler, A., Hengartner, H., Aguet, M., and Zinkernagel, R. M., 1995. Antiviral protection by vesicular stomatitis virus-specific antibodies in alpha/beta interferon receptor-deficient mice. J Virol 69, 2153-8.
- Su, H. C., Nguyen, K. B., Salazar-Mather, T. P., Ruzek, M. C., Dalod, M. Y., and Biron, C. A., 2001. NK cell functions restrain T cell responses during viral infections. Eur J Immunol 31, 3048-55.
- Takeda, K., Kaisho, T., and Akira, S., 2003. Toll-Like Receptors. Annu Rev Immunol 9, 9.
- Takeuchi, O., Hoshino, K., and Akira, S., 2000. Cutting edge: TLR2-deficient and MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection. J Immunol 165, 5392-6.
- Tyler, K. L., Bronson, R. T., Byers, K. B., and Fields, B., 1985. Molecular basis of viral neurotropism: experimental reovirus infection. Neurology 35, 88-92.
- Tyler, K. L., Virgin, H. W. T., Bassel-Duby, R., and Fields, B. N., 1989. Antibody inhibits defined stages in the pathogenesis of reovirus serotype 3 infection of the central nervous system. J Exp Med 170, 887-900.
- Whitmire, J. K., Asano, M. S., Murali-Krishna, K., Suresh, M., and Ahmed, R., 1998. Long-term CD4 Th1 and Th2 memory following acute lymphocytic choriomeningitis virus infection. J Virol 72, 8281-8.





С



## Fig.2



С

memory cell response to LCMV



# Fig.3



Fig.4

